F038. Platelet Rich Plasma

The discussion revolves around the legal implications and regulatory environment of Platelet Rich Plasma (PRP) in regenerative medicine, touching on the prevalence of off-label uses for skin and hair treatments. The PRP market is anticipated to expand significantly, yet treatment costs are often not covered by insurance. PRP, defined as a concentrated solution derived from whole blood, has particular FDA guidelines it must adhere to, including minimal manipulation of the product. Practitioners must use FDA-cleared devices and abide by strict definitions to avoid legal consequences. Off-label usage is common, but practitioners are cautioned on marketing claims and the necessity of using only FDA-approved systems to mitigate liability risks. The conversation briefly introduces exosomes—vesticles involved in cellular communication—with an emphasis on legal issues surrounding their use in skin and hair treatments. Currently, no exosome products are FDA approved, emphasizing the need for caution and further research in this area. The importance of using correctly regulated devices and understanding the implications of both PRP and exosomes for regenerative treatments is underscored, with a call for more studies to standardize practices within the industry.